Intervention not reported
Overall survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The intervention showed no clear difference in overall survival (high certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · people with non‐rhabdomyosarcoma soft tissue sarcoma
1 finding from 1 review
Intervention not reported
Disease‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Progression‐free survival · people with non‐rhabdomyosarcoma soft tissue sarcoma
The intervention showed no clear difference in progression‐free survival (high certainty).
1 finding from 1 review
Intervention not reported
Non‐hematologic toxicity grade 3 to 4 · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Health‐related quality of life · people with non‐rhabdomyosarcoma soft tissue sarcoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Mortality (after 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in mortality (after 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Relapse or death (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention probably leads to lower relapse or death (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality ‐ overall analysis (at 3 years) · Patients with refractory/relapsed Hodgkin lymphoma
The intervention showed no clear difference in treatment‐related mortality ‐ overall analysis (at 3 years) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events not estimable · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Intervention not reported
Quality of life not reported · Patients with refractory/relapsed Hodgkin lymphoma
1 finding from 1 review
Intervention not reported
Overall survival · Adult patients with follicular lymphoma
The intervention showed no clear difference in overall survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Treatment‐related mortality · Adult patients with follicular lymphoma
The intervention showed no clear difference in treatment‐related mortality (moderate certainty).
1 finding from 1 review
Intervention not reported
Progression‐free survival · Adult patients with follicular lymphoma
The intervention probably leads to lower progression‐free survival (moderate certainty).
1 finding from 1 review
Intervention not reported
Secondary malignancies AML/MDS · Adult patients with follicular lymphoma
The intervention showed no clear difference in secondary malignancies AML/MDS (low certainty).
1 finding from 1 review
Intervention not reported
Secondary malignancies Solid cancer · Adult patients with follicular lymphoma
The intervention showed no clear difference in secondary malignancies Solid cancer (low certainty).
1 finding from 1 review
Intervention not reported
Adverse events · Adult patients with follicular lymphoma
1 finding from 1 review